title: Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study.
abstract: 1. The safety profile of terbinafine, the first orally active allylamine, was monitored in the UK in a post-marketing setting. The study recruited 10,361 patients, a number which is approximately 5% of the population who received oral terbinafine in the UK during the period of the study. 2. Follow-up data were available on 9,879 patients. During the course of the study 14.5% patients reported medical events. 49% were thought to be possibly or probably related to terbinafine treatment. Seventy-four of the events (< 1%) were classified as 'serious' and of these only five were assessed as possibly or probably related to treatment. 3. Taste disturbance occurred in 0.6% of the patients and emerged as the only new adverse reaction probably attributable to terbinafine: this was significantly commoner in females and reversible on stopping treatment, with a median time to recovery of 42 days. 4. The study approach successfully combined hospital based dermatology outpatient and general practice centres. Source data verification was conducted on 13% of the cohort selected randomly. 5. Overall, the denominator-based description of the safety profile in actual practice shows terbinafine to be well-tolerated against a wide background of age and coexisting illness.
authors.affiliation: Sandoz Pharmaceuticals UK Ltd, Frimley, Camberley, UK.
authors.forename: D P
authors.initials: DP
authors.lastname: O'Sullivan
authors.forename: C A
authors.initials: CA
authors.lastname: Needham
authors.forename: A
authors.initials: A
authors.lastname: Bangs
authors.forename: K
authors.initials: K
authors.lastname: Atkin
authors.forename: F D
authors.initials: FD
authors.lastname: Kendall
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D000077291:Terbinafine; D014344:Trypanocidal Agents / Q000009:adverse effects*
chemical_list: D000935:Antifungal Agents; D009281:Naphthalenes; D014344:Trypanocidal Agents; D000077291:Terbinafine